Pancreatic Cancer Research

ResearcherUtrecht UniversityActive in the last 2 years

Izaak Quintus Molenaar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1585-7184; OpenAlex author ID A5072899975. Sources: ClinicalTrials.gov.

Their work

Papers
148 (first author 3, last author 26)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
343
Papers, trials and grants by year

2014: 4 papers, 1 trial · 2015: 4 papers · 2016: 8 papers · 2017: 3 papers · 2018: 7 papers · 2019: 8 papers · 2020: 8 papers · 2021: 9 papers · 2022: 14 papers · 2023: 16 papers · 2024: 25 papers · 2025: 23 papers · 2026: 19 papers

Papers 50 of 148

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. Chemotherapy After Resection of Pancreatic Ductal Adenocarcinoma: Impact of Different Regimens in a Real-World Population. Co-author DOI 10.1002/jso.70391↗
  3. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  4. The impact of lower household income and distance to hospital on treatment and survival in patients with localized pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.116956↗
  5. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  6. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Last author DOI 10.1016/j.ejso.2025.111165↗
  7. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  8. Does ductal subtype predict outcomes after resection of IPMN-derived pancreatic cancer? An international multi-center retrospective study. Co-author DOI 10.1016/j.hpb.2026.08.011↗
  9. Pancreatic ductal adenocarcinoma: Clinical trials to watch. First author DOI 10.1016/j.medj.2026.101268↗
  10. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  11. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  12. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  13. Informing Decision-making for Transected Margin Reresection in Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: An International Multicenter … Co-author DOI 10.1097/sla.0000000000006532↗
  14. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  15. Implications of Neoadjuvant Therapy on Prognostic Factors in Pancreatic Ductal Adenocarcinoma: A Path Towards Personalized Prognostication. Co-author DOI 10.1097/sla.0000000000006660↗
  16. Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18639-1↗
  17. ASO Visual Abstract: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18791-8↗
  18. ASO Author Reflections: The Impact of Perioperative Treatment on Recurrence Treatment for Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18798-1↗
  19. The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study. Co-author DOI 10.3390/cancers18040700↗
  20. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  21. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  22. Survival scenarios of patients with localized and metastatic pancreatic adenocarcinoma: A population-based study. Co-author DOI 10.1002/ijc.35267↗
  23. Prehabilitation Targets Associated with the Omission of Adjuvant Chemotherapy After Surgery for Pancreatic Cancer. Co-author DOI 10.1007/s12029-025-01357-y↗
  24. Adjuvant therapy after resection of intraductal papillary mucinous neoplasm-derived pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ctrv.2025.102969↗
  25. Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based … Co-author DOI 10.1016/j.ejca.2025.115385↗
  26. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  27. Tumor gene expression is associated with venous thromboembolism in patients with ductal pancreatic adenocarcinoma. Co-author DOI 10.1016/j.thromres.2024.109240↗
  28. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  29. Recognizing IPMN-derived pancreatic cancer as a specific entity requiring prospective clinical studies: a call for international collaboration. Co-author DOI 10.1093/jnci/djaf037↗
  30. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  31. Evaluation of Short and Long-term Outcomes After Resection in Patients With Locally Advanced Versus (Borderline) Resectable Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000006289↗
  32. Defining the Minimal and Optimal Thresholds for Lymph Node Resection and Examination for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: A M… Co-author DOI 10.1097/sla.0000000000006295↗
  33. Perineural Invasion is an Important Prognostic Factor in Patients With Radically Resected (R0) and Node-negative (pN0) Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006320↗
  34. Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006687↗
  35. Routine Imaging After Resection of Pancreatic Ductal Adenocarcinoma: Nationwide Utilization and Survival Analysis. Last author DOI 10.1097/sla.0000000000006772↗
  36. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  37. Patient preferences for pancreatic cancer treatment (PERSEUS): a multicenter discrete choice experiment. Co-author DOI 10.1186/s12955-025-02440-5↗
  38. Defining and Predicting Early Recurrence for Optimal Treatment Strategies for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: An Internation… Co-author DOI 10.1245/s10434-024-16649-z↗
  39. Association Between Adjuvant Therapy and Survival in Resected Pancreatic Ductal Adenocarcinoma After Different Types and Durations of Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-025-17439-x↗
  40. Incidence and Outcomes of Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Compared with Tubular and Colloid Intraductal Papillary Mucinous N… Co-author DOI 10.1245/s10434-025-17810-y↗
  41. The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells14090632↗
  42. Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. Last author DOI 10.6004/jnccn.2024.7091↗
  43. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  44. 31P MR Spectroscopy in the Pancreas: Repeatability, Comparison With Liver, and Pilot Pancreatic Cancer Data. Co-author DOI 10.1002/jmri.29326↗
  45. Radiation response assessment of organoids derived from patients with pancreatic cancer. Co-author DOI 10.1016/j.ctro.2024.100829↗
  46. Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancrea… Co-author DOI 10.1016/j.surg.2024.01.029↗
  47. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1038/s41575-023-00856-2↗
  48. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  49. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  50. An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer. Co-author DOI 10.1093/jnci/djae166↗

Trials 1

  1. Pancreatic Cancer Recurrence in the Netherlands Principal investigator NCT04605237↗

Closest collaborators

The 25 strongest of 343 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 105 shared papers, 2014–2026 · strength 14.16
  2. Hjalmar C. van Santvoort · 93 shared papers, 2014–2026 · strength 13.67
  3. Lois A. Daamen · 68 shared papers, 2017–2026 · strength 11.99
  4. Bas Groot Koerkamp · 56 shared papers, 2017–2026 · strength 8.02
  5. Ignace H. J. T. de Hingh · 62 shared papers, 2014–2026 · strength 7.61
  6. Martijn W.J. Stommel · 45 shared papers, 2019–2026 · strength 6.46
  7. Johanna W. Wilmink · 41 shared papers, 2016–2026 · strength 5.80
  8. Vincent Erwin de Meijer · 39 shared papers, 2020–2026 · strength 5.62
  9. Bert A. Bonsing · 41 shared papers, 2014–2026 · strength 5.09
  10. Vincent P. Groot · 31 shared papers, 2017–2026 · strength 4.76
  11. Casper H.J. van Eijck · 38 shared papers, 2014–2026 · strength 4.73
  12. Ammar A. Javed · 24 shared papers, 2018–2026 · strength 4.32
  13. Paul C. M. Andel · 22 shared papers, 2024–2026 · strength 4.30
  14. Christopher Lee Wolfgang · 26 shared papers, 2017–2026 · strength 4.23
  15. Sebastiaan Festen · 30 shared papers, 2016–2026 · strength 4.13
  16. Joseph R. Habib · 21 shared papers, 2023–2026 · strength 4.08
  17. Geert Kazemier M · 27 shared papers, 2016–2026 · strength 3.78
  18. Judith de Vos‐Geelen · 25 shared papers, 2016–2026 · strength 3.62
  19. Hanneke W.M. van Laarhoven · 27 shared papers, 2016–2026 · strength 3.59
  20. Ingmar Florin Rompen · 18 shared papers, 2024–2026 · strength 3.45
  21. Iris W.J.M. van Goor · 20 shared papers, 2021–2026 · strength 3.29
  22. Thijs J. Schouten · 19 shared papers, 2021–2026 · strength 3.16
  23. Robert C. Verdonk · 18 shared papers, 2022–2026 · strength 3.10
  24. Nadia Haj Mohammad · 21 shared papers, 2016–2026 · strength 2.59
  25. Thomas F. Stoop · 14 shared papers, 2024–2026 · strength 2.47

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.